The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009Plasma Biomarker Screen for Neurodegeneration and Signaling Proteins
Objective/Rationale:
The cells and tissues of the body can “communicate” with one another using small secreted proteins that can be found in the blood. There are several hundred of these cellular... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Fisetin and Derivatives as Neuroprotective Drugs for the Treatment of Parkinson's Disease
Objective/Rationale:
Glutathione (GSH) is an antioxidant produced naturally by cells thereby providing them with a defense against oxidative stress. There is good evidence that GSH levels decrease in... -
Therapeutics Development Initiative, 2012Lead Optimization for a Parkinson's Disease Therapeutic
Objective/Rationale:
CuII(atsm) has the potential to delay disease progression in Parkinson’s disease, based on extensive pre-clinical model data. CuII(atsm) has been shown to significantly improve... -
Research Grant, 2025Path to Prevention (P2P) Platform Trial: A Phase 2A, Randomized, Double Blind, Placebo Controlled Study to Evaluate Investigational Interventions in Early-Stage Neuronal Alpha-Synuclein Disease (NSD)
Study Rationale: Assess the impact of putative NSD therapies in participants with Early Stage NSD on Dopamine Transporter Single-photon emission computed Tomography (DAT SPECT) imaging, clinical...
-
Clinical Intervention Awards, 2007The PARKFIT Study: Effectiveness of an Active Lifestyle Promotion Program for Patients with Parkinson’s disease
Objective/Rationale:
Parkinson's patients are inclined toward a sedentary lifestyle. This is due to a combination of both physical handicaps (e.g. walking difficulties) and mential impairments (e.g... -
Resource: Utilizing DATATOP Biospecimens, 2011Validation of Alpha-synuclein Oligomers as Biomarker for Parkinson’s Disease
Objective/Rationale:
We have reported recently higher levels of α-synuclein oligomers species in cerebral spinal fluid (CSF) from patients clinically diagnosed with Parkinson’s disease (PD) versus...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.